Charmacy Pharmaceutical Co., Ltd. provided earnings guidance for the ended 31 December 2021. For the period, the group is expected to report a net profit attributable to the shareholders of the parent company of approximately RMB 21.00 million to RMB 25.00 million for the Year, representing a decrease of approximately 38% to 48% as compared with that of the year ended 31 December 2020.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
9.37 HKD | -1.37% | +7.70% | -27.70% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-27.70% | 129M | |
-37.88% | 13.99B | |
-32.23% | 10.67B | |
-20.52% | 6.75B | |
+12.54% | 6.29B | |
-11.51% | 5.88B | |
+75.00% | 4.96B | |
-2.34% | 4.61B | |
-9.20% | 3.74B | |
-19.40% | 3.16B |
- Stock Market
- Equities
- 2289 Stock
- News Charmacy Pharmaceutical Co., Ltd.
- Charmacy Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Ended 31 December 2021